Portal de Periódicos da CAPES

Hepatitis B vaccination of patients with chronic liver disease

1998; Wiley; Volume: 4; Issue: 5 Linguagem: Inglês

10.1002/lt.500040515

2331-3293

Emmet B. Keeffe, David Krause,

Hepatitis C virus research

Liver Transplantation and SurgeryVolume 4, Issue 5 p. 437a-439 Letter To The EditorFree Access Hepatitis B vaccination of patients with chronic liver disease Emmet B. Keeffe MD, Emmet B. Keeffe MD Stanford University Medical Center, Stanford, CA, SmithKline Beecham Pharmaceuticals, Collegeville, PASearch for more papers by this authorDavid S. Krause, David S. Krause Stanford University Medical Center, Stanford, CA, SmithKline Beecham Pharmaceuticals, Collegeville, PASearch for more papers by this author Emmet B. Keeffe MD, Emmet B. Keeffe MD Stanford University Medical Center, Stanford, CA, SmithKline Beecham Pharmaceuticals, Collegeville, PASearch for more papers by this authorDavid S. Krause, David S. Krause Stanford University Medical Center, Stanford, CA, SmithKline Beecham Pharmaceuticals, Collegeville, PASearch for more papers by this author First published: 30 December 2003 https://doi.org/10.1002/lt.500040515Citations: 39AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Chalasani N, Smallwood G, Halcomg J, Fried MW, Boyer TD. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation. Liver Transplant Surg 1998; 4: 128–132. 10.1002/lt.500040208 CASPubMedWeb of Science®Google Scholar 2 Van Thiel DH. Vaccination of patients with liver disease: Who, when, and how. Liver Transplant Surg 1998; 4: 185–187. 10.1002/lt.500040213 CASPubMedWeb of Science®Google Scholar 3 Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881–886.MEDLINE 10.1002/hep.510270336 CASPubMedWeb of Science®Google Scholar 4 Engerix-B Prescribing Information. Collegeville PA: SmithKline Beecham Pharmaceuticals. 1997;. Google Scholar 5 Andre FE. Summary of safety and efficacy data on a yeast derived hepatitis B vaccine. Am J Med 1989; 98(suppl 3A): 14S. 10.1016/0002-9343(89)90525-1 Web of Science®Google Scholar 6 McMahon BJ, Wainwright RB. Protective efficacy of hepatitis B vaccines in infants, children and adults. In: RW Ellis eds. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker. 1993; 243–261. Web of Science®Google Scholar 7 Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997; 26 (suppl 1): 2S–10S .MEDLINE PubMedWeb of Science®Google Scholar 8 CDC. Hepatitis A among persons with hemophilia who received clotting factor concentrate—United States, September–December 1995. MMWR 1996; 45: 29–32. PubMedGoogle Scholar 9 Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995; 90: 201–205.MEDLINE CASPubMedWeb of Science®Google Scholar Citing Literature Volume4, Issue5September 1998Pages 437a-439 ReferencesRelatedInformation